TABLE 5.
CheckMate 017 [ 83 ] | CheckMate 057 [ 84 ] | CheckMate 026 [ 87 ] |
Keynote
010 [ 85 ] |
Keynote
024 [ 86 ] |
OAK
[ 88 ] |
|||||||
Population | sNSCLC | nsNSCLC | PD-L1 ≥1% | PD-L1 ≥1% | PD-L1 ≥50% | NSCLC | ||||||
Treatment line | ≥Second-line | ≥Second-line | First-line | ≥Second-line | First-line | ≥Second-line | ||||||
Drug | Nivo | Doce | Nivo | Doce | Nivo | Chemo | Pembro | Doce | Pembro | Chemo | Atezo | Doce |
ORR % | 20 | 9 | 19 | 12 | 26.1 | 33.5 | 18 | 9 | 44.8 | 27.8 | 14 | 13 |
PFS months | 3.5 | 2.8 | 2.3 | 4.2 | 4.2 | 5.9 | 3.9, 4.0# | 4.0 | 10.3 | 6.0 | 2.8 | 4.0 |
Overall
survival
months |
9.2 | 6.0 | 12.2 | 9.4 | 14.4 | 13.2 | 10.4, 12.7# | 8.5 | 80.2%¶ | 72.4%¶ | 13.8 | 9.6 |
PD-L1 expression | ||||||||||||
Antibody | 28-8 | 28-8 | 28-8 | 22C3 | 22C3 | SP142 | ||||||
Platform manufacturer | Dako | Dako | Dako | Dako | Dako | Ventana | ||||||
Analysed cells | Tumour cells | Tumour cells | Tumour cells | Tumour cells | Tumour cells | Tumour and immune cells | ||||||
Thresholds | 1%, 5%, 10% | 1%, 5%, 10% | 1%, 5%, 10% | 1%, 50% | 1%, 50% | Tumour: 1%, 5%,
50%; Immune: 1%, 5%, 10% |
||||||
Sampling time | Pretreatment | Pretreatment | Pretreatment | Any | Pretreatment | Pretreatment | ||||||
Preanalytic | Archival FFPE | Archival FFPE | Archival FFPE | Archival or new | Archival or new | Archival or new |
ORR: objective response rate; PFS: progression-free survival; PD-L1: programmed cell death ligand 1; NSCLC: nonsmall cell lung cancer; Nivo: nivolumab; Doce: docetaxel; Chemo: chemotherapy; Pembro: pembrolizumab; Atezo: atezolizumab; FFPE: formalin-fixed paraffin-embedded. #: two doses of pembrolizumab were tested (2 mg·kg−1 and 10 mg·kg−1); ¶: 6-month overall survival rate.